Benefits
Menopause poses many physical and psychological problems for women. The use of hormone therapy (HT) such as the use of estrogen (ET) and progestogens therapies (PT) provide a solution to most of these problems. HT is useful for patients in the early years of menopause that is, between the ages of 50 and 59 years (Rifkin, & Lazris, 2014). A patient suffering from abnormal uterine bleeding (AUB) characterized by heavy menstrual bleeding, or prolonged bleeding can use HT to treat the disorder (Buttaro, 2012). AUB if left untreated result in anaemia diminishes the sexual intercourse urge thus diminishing the quality of life of the patient. The miscommunication of hypothalamus, pituitary, and ovaries is the cause of the irregular cycles thus treatment comprising of both medical and HT helps cure the ailment. The hormonal management used are GnRH agonists, contraceptives, and oral progestogens (Buttaro, 2012). The medical and HT must only be used by patients not suffering from fibroids and other advanced levels of the sickness that warrant surgical treatments. Patients with risks of osteoporosis, which comprise of fractures as an adult, Cushing syndrome among other bone problems should use ET for at least five years to make the bones stronger, but patients over the age of 65 should not use ET.
Risks
The primary risks associated with HT is the elevation of chronic disorders such as stroke, cancers, and age over 65 (Newson, 2016). A patient whose record demonstrates that they have suffered a stroke, or are at higher risks of osteoporosis such as Caucasians over the age of 50 years and are in their post-menopause stages should not use HT. The use of HT for treatment of osteoporosis for all women over the age of 65 years as it would increase their chances of suffering from the chronic disorders (Rifkin, & Lazris, 2014). The use of BMD tests helps the physicians to make a better judgment in the treatment of post-menopause patients who are between the ages of 59 and 65 years and avoid HT if the patient is at a higher risk of chronic and osteoporosis disorders.
Delegate your assignment to our experts and they will do the rest.
References
Buttaro, T. M. (2012). Primary care: A collaborative practice . St. Louis, Mo: Elsevier/Mosby.
Newson, L. (2016, February 26). Hormone Replacement Therapy (Risks and Benefits) . HRT. Patient.info . Retrieved October 9, 2017, from https://patient.info/doctor/hormone-replacement-therapy-including-benefits-and-risks
Rifkin, E., & Lazris, A. (2014). Interpreting health benefits and risks: A practical guide to facilitate doctor-patient communication .
